Quote | Oncopeptides (OTCMKTS:ONPPF)
Last: | $0.265 |
---|---|
Change Percent: | 0.0% |
Open: | $0.265 |
Close: | $0.265 |
High: | $0.265 |
Low: | $0.265 |
Volume: | 200 |
Last Trade Date Time: | 05/03/2024 03:00:00 am |
News | Oncopeptides (OTCMKTS:ONPPF)
Oncopeptides ( OTC:ONPPF ) said a majority of a panel of the U.S. Food and Drug Administration (FDA) considered that data from a phase 3 trial called OCEAN did not confirm a favorable benefit-risk profile of the company's blood cancer therapy Pepaxto. Pepaxto&...
The following slide deck was published by Oncopeptides AB (publ) in conjunction with their 2022 Q2 earnings call. For further details see: Oncopeptides AB (publ) 2022 Q2 - Results - Earnings Call Presentation
Message Board Posts | Oncopeptides (OTCMKTS:ONPPF)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Oncopeptides Company Name:
ONPPF Stock Symbol:
OTCMKTS Market:
FDA announces an Oncologic Drugs Advisory Committee meeting to discuss benefit/risk profile of Oncopeptides' Pepaxto PR Newswire STOCKHOLM , July 20, 2022 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on resear...
Oncopeptides rescinds voluntary withdrawal of Pepaxto in the US - no intent to market in the US at this time PR Newswire STOCKHOLM , Jan. 21, 2022 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and deve...
Oncopeptides presents phase 3 OCEAN study results at the IMW meeting PR Newswire STOCKHOLM , Sept. 11, 2021 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat he...